Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 10/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23744528 | 0.91 | KDM4E (0.52) | CHRM4CHRM2CHRM1KDM4EALDH1A1 | |
| SCHEMBL23744733 | 0.91 | KDM4E (0.52) | CHRM4CHRM2CHRM1KDM4EALDH1A1 | |
| SCHEMBL26087104 | 0.90 | CHRM2 (0.45) | CHRM4CHRM2CHRM1 | |
| SCHEMBL23744126 | 0.90 | CHRM4 (0.58) | CHRM4CHRM2CHRM1 | |
| SCHEMBL23744545 | 0.89 | KDM4E (0.51) | KDM4EALDH1A1HPGDHSD17B10SIGMAR1 | |
| SCHEMBL23744522 | 0.87 | CHRM2 (0.60) | CHRM4CHRM2CHRM1 | |
| SCHEMBL23744637 | 0.80 | CHRM4 (0.45) | CHRM4CHRM2CHRM1KDM4EALDH1A1 | |
| SCHEMBL23744527 | 0.79 | CHRM4 (0.52) | CHRM4CHRM2CHRM1ALDH1A1SIGMAR1 | |
| SCHEMBL23744726 | 0.79 | CHRM4 (0.52) | CHRM4CHRM2CHRM1ALDH1A1SIGMAR1 | |
| SCHEMBL26087163 | 0.79 | HCAR2 (0.44) | CHRM4CHRM2CHRM1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | CHRM4 1/4885CHRM2 2/4885CHRM1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.